Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Articles

Health Canada Approves Goserelin Acetate for High-Risk, ER+ Early and Advanced Breast Cancer

May 8th 2024

Health Canada has approved an sNDA for goserelin acetate 10.8 mg every 12 weeks for ER-positive early breast cancer with a high risk of recurrence or advanced breast cancer.

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

April 29th 2024

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer

April 25th 2024

CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

April 16th 2024

Adjuvant nivolumab extended DFS, NUTRFS, and DMFS vs placebo and showed for the first time an improvement in OS in patients with high-risk muscle-invasive urothelial cancer.

FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma

April 12th 2024

The FDA’s ODAC voted that data support the use of minimal residual disease as an end point to support accelerated approval of treatments in multiple myeloma.

Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC

April 12th 2024

The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT

April 10th 2024

Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.

FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer

April 9th 2024

The FDA has granted fast track designation to PT217 for patients with extensive stage small cell lung cancer with disease progression.

Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer

April 9th 2024

Mirvetuximab soravtansine plus pembrolizumab displays efficacy in recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer.

Preliminary Data Hint at PFS Benefit With Personalized Neoantigen Vaccine in Metastatic MSS CRC

April 2nd 2024

Treatment with GRANITE showed early signals of activity following frontline induction chemotherapy in metastatic microsatellite stable colorectal cancer.

Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC

March 28th 2024

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

Amivantamab Plus Chemo Nearly Doubles Time to Treatment Discontinuation, Need for Subsequent Therapy in EGFR Exon 20+ NSCLC

March 20th 2024

Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.

FDA Accepts BLA Resubmission for Denileukin Diftitox in Relapsed/Refractory Cutaneous T-Cell Lymphoma

March 18th 2024

The FDA has accepted the resubmission of the BLA seeking the approval of denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma.

Olaparib Plus Cediranib Falls Short in All-Comers With Platinum-Resistant or Refractory Ovarian Cancer

March 16th 2024

Olaparib plus cediranib failed to improve PFS and OS vs chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

FDA ODAC Committee Votes In Favor of Benefit-Risk Profile of Imetelstat in Lower-Risk MDS

March 14th 2024

The FDA’s Oncologic Drugs Advisory Committee voted in favor of imetelstat for select patients with lower-risk myelodysplastic syndrome.

Targeted Delivery of IL-12 Shows Preliminary Antitumor Activity in Advanced Solid Tumors

March 11th 2024

A high proportion of patients with metastatic solid tumors experienced stable disease following treatment with the immunocytokine in the DODEKA trial.

Artificial Intelligence in Prostate Cancer Pathology: Friend or Foe?

March 9th 2024

Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.

Piecing the Puzzle Together: Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer

March 9th 2024

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

UV1 Vaccination Plus Nivolumab/Ipilimumab Falls Short in Metastatic Melanoma

March 7th 2024

The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma.

NEXT PAGE
PREVIOUS PAGE